NMD3

Across TCGA pan-cancer cohorts, NMD3 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of NMD3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where NMD3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NMD3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where NMD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NMD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.357	<.001	12	view →
COAD	Female	III,IV	+0.450	<.001	11	view →
HNSC	Male	III,IV	+0.360	<.001	11	view →
LSCC	Male	II,III,IV	+0.547	<.001	8	view →
LUAD	Male	III,IV	+0.324	<.001	8	view →
PDAC	Female	All	−0.224	.006	4	view →
OV	All	All	+0.220	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

NMD3–CCRCC

Open the CCRCC breakdown →